Truist Securities increased the price target for Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX), a $121 ...

Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Houston-based Vertex Energy, which operates a 75,000 b/d refinery ... Year-to-date, Gulf Coast ULSD has fetched an average price of $100.10/bbl, providing a gross margin over West Texas ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its ...

Recent acquisitions are masking Vertex's slower organic growth, which doesn't justify its current stock price. Without acquisitions, Vertex's new customer expansion in 2024 has been very limited.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

This anticipated adoption, along with a projected modest market penetration, underpins the increased price target for Vertex Pharmaceuticals’ stock, contributing to Fein’s Buy rating.